COPD and Comorbidities: Relating Mechanisms and Treatment

Author(s): Velin Stratev*, Valentina Dimitrova, Diana Petkova.

Journal Name: Current Respiratory Medicine Reviews

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Despite being a disease with the constantly rising social burden and mortality, COPD is also associated with a number of other conditions known as comorbidities. COPD and other diseases often share similar risk factors, such as smoking and aging, which leads to increased prevalence of comorbidities. The key pathogenic mechanisms of COPD are chronic inflammation and oxidative stress and they also contribute significantly to the development of accompanying diseases. Through complex interactions, COPD increases the risk for certain comorbidities and they, in turn, have a negative impact on health status and contribute to mortality in COPD patients. Proper treatment of comorbidities may have a beneficial effect on COPD natural course and progression. Here we review the prevalence of the most common comorbidities of COPD; their interrelating mechanism and the current advances of the treatment in terms of co-existence.

Keywords: Chronic inflammation, comorbidities, COPD, cardiovascular disease, oxidative stress, treatment.

[2]
Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013; 1: 73-83.
[3]
Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 2007; 370: 765-73.
[4]
Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet 2005; 366: 1875-81.
[5]
Franchi M. EFA Book on chronic obstructive pulmonary disease in Europe Sharing and Caring. Brussels: European Federation of Airway Diseases 2010.
[6]
Aryal S, Diaz-Guzman E, David M. Prevalence of COPD and comorbidity. In: Rabe K, Wedzicha J, Wouters E, Eds. COPD and comorbidity Mannino: European Respiratory Monograph Number 59 March. 2013.
[7]
Agusti A, Calverley P, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
[8]
Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality. Kaiser Permanente Medical Care Program Chest 2005; 128: 2068-75.
[9]
McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD, operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-5.
[10]
Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-53.
[11]
Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015-26.
[12]
Van Pottelberge GR, Bracke KR, Joos GF, et al. The role of dendritic cells in the pathogenesis of COPD: liaison officers in the front line. COPD 2009; 6: 284-90.
[13]
Barnes PJ. COPD: Inflammatory mechanisms and systemic consequences. In: Rabe K, Wedzicha J, Wouters E, Eds. COPD and comorbidity European Respiratory Monograph Number 59 March. 2013.
[14]
van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: A chronic systemic inflammatory disease. Respiration 2008; 75: 224-38.
[15]
Thomsen M, Dahl M, Lange P, et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 982-8.
[16]
Fogarty AW, Jones S, Britton JR, et al. Systemic inflammation and decline in lung function in a general population: A prospective study. Thorax 2007; 62: 515-20.
[17]
Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29: 527-34.
[18]
Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 269-78.
[19]
Sin DD, Leung R, Gan WQ, et al. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007; 7: 13.
[20]
Hurst JR, Donaldson GC, Perea WR, et al. Utility of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867-74.
[21]
Bowler RP, Barnes PJ, Crapo JD. The role of oxidative stress in chronic obstructive pulmonary disease. J COPD 2004; 2: 255-77.
[22]
MacNee W. Oxidants. In: Stockley RA, Rennard SI, Rabe K, Celli B, Eds. Chronic obstructive pulmonary disease. New Jersey: Blackwell Publishing Ltd 2007; pp. 367-84.
[23]
Stratev V, Petev J, Galcheva S, Peneva M. Increasing oxidative stress and inflammation in patients with exacerbated chronic obstructive pulmonary disease (COPD) and their association with lung function. Eur Respir J 2012; 40(Suppl. 56): 4595.
[24]
Morrison D, Rahman I, Lannan S, et al. Epithelial permeability, inflammation and oxidant stress in the airspaces of smokers. Am J Respir Crit Care Med 1999; 159: 473-9.
[25]
Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003; 29: 88-97.
[26]
Terashima T, Klut ME, English D, et al. Cigarette smoking causes sequestration of polymorphonuclear leukocytes released from the bone marrow in lung micro-vessels. Am J Respir Cell Mol Biol 1999; 20: 171-7.
[27]
Tsukagoshi H, Kawata T, Shimizu Y, et al. 4-Hydroxy-2-nonenal enhances fibronectin production by IMR-90 human lung fibroblast party via activation of epidermal growth factor receptor-linked extracellular signal-regulated kinase p44=42 pathway. Toxicol Appl Pharmacol 2002; 184: 127-35.
[28]
Agusti AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 485-9.
[29]
Mochida-Nishimura K, Sureweicz K, Cross JV, et al. Differential activation of MAP kinase signaling pathways and nuclear factor-kappaB in broncho-alveolar cells of smokers and nonsmokers. Mol Med 2001; 7: 177-85.
[30]
Miłkowska-Dymanowska J, Białas A, Makowska J, et al. Geroprotectors as a therapeutic strategy for COPD - where are we now? Clin Interv Aging 2017; 12: 1811-7.
[31]
Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640-6.
[32]
Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70.
[33]
Sin DD, Man SFP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
[34]
Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-9.
[35]
Battaglia S, Basile M, Scichilone N, Bellia V. Prevalence of co-morbidities and severity of COPD. COPD 2015; 12(4): 390-4.
[36]
Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-94.
[37]
Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003; 21: 1012-6.
[38]
Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol 2017; 69(5): 699-705.
[39]
Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis. JAC 2009; 54: 2129-38.
[40]
Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
[41]
Ridker P, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
[42]
Agustı ´A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One 2012; 7: e37483-9.
[43]
Lahousse L, van den Bouwhuijsen Q, Loth DW, et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: The rotterdam study. Am J Respir Crit Care Med 2013; 187(1): 58-64.
[44]
Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
[45]
Casanova C, De Torres JP, Navarro J, et al. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 1004-10.
[46]
MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 50-60.
[47]
Kameda K, Matsunaga T, Abe N, et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodeling. Eur Heart J 2003; 24: 2180-5.
[48]
Lattimore J-DL, Wilcox I, Nakhla S, et al. Repetitive hypoxia increases lipid loading in human macrophages - a potentially atherogenic effect. Atherosclerosis 2005; 179: 255-9.
[49]
Maclay J, MacNee W. Assessment of cardiovascular comorbidity. In: Rabe K, Wedzicha J, Wouters E, Eds. COPD and comorbidity. European Respiratory Monograph 2013; Number 59: pp. 46
[50]
Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32-47.
[51]
Young RP, Hopkins RJ. Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. Expert Rev Respir Med 2013; 7(5): 533-44.
[52]
Carlson AA, Smith EA, Reid DJ. The stats are in: An update on statin use in COPD. Int J Chron Obstruct Pulmon Dis 2015; 10: 2277-84.
[53]
Maneechotesuwan K, Wongkajornsilp A, Adcock IM, et al. Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD. Chest 2015; 148(5): 1164-76.
[54]
Mroz RM, Lisowski P, Tycinska A, et al. Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. J Physiol Pharmacol 2015; 66(1): 111-28.
[55]
Lipworth B, Wedzicha J, Devereux G, et al. Beta-blockers in COPD: time for reappraisal. Eur Respir J 2016; 48: 880-8.
[56]
Dransfield MT, McAllister DA, Anderson JA, et al. β-blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. An observational substudy of SUMMIT. Ann Am Thorac Soc 2018; 15(5): 608-14.
[57]
Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63: 301-5.
[58]
Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-7.
[59]
Andell P, Erlinge D, Smith JG, et al. β-blocker use and mortality in COPD patients after myocardial infarction: A Swedish nationwide observational study. J Am Heart Assoc 2015; 4 e001611
[60]
Aronow WS. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: Diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest Heart Fail 2003; 9: 142-7.
[61]
Zhang J, Zhao G, Yu X, et al. Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease. Respirology 2012; 17: 715-20.
[62]
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006; 23: 469-80.
[63]
Wei W, Kim Y, Boudreau N. Association of smoking with serum and dietary levels of antioxidants in adults: NHANES III, 1988-1994. Am J Public Health 2001; 91: 258-64.
[64]
Wells CE, Emma H. Metabolic syndrome and diabetes mellitus in COPD. In: Rabe K, Wedzicha J, Wouters E, Eds. COPD and comorbidity Baker: European Respiratory Monograph Number 59 March. 2013.
[65]
Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: The critical role of abdominal obesity. Am J Respir Crit Care Med 2009; 179(6): 509-16.
[66]
World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation. 2006 www.who.int/diabetes/publications/Definition
[67]
Schokker DF, Visscher TL, Nooyens AC, et al. Prevalence of overweight and obesity in the Netherlands. Obes Rev 2007; 8: 101-8.
[68]
Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention 2012. Available from http: //www.cdc.gov/brfss/ [accessed 2018 July 20].
[69]
Baffi CW, Wood L, Winnica D, et al. Metabolic syndrome and the lung chest 2016; 149(6): 1525-34.
[70]
Malaviya R, Laskin JD, Laskin DL. Anti-TNFα therapy in inflammatory lung diseases. Pharmacol Ther 2017; 180: 90-8.
[71]
MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2013; 45(3): 291-300.
[72]
Grattagliano I, Palmieri VO, Portincasa P, et al. Oxidative stress-induced risk factors associated with the metabolic syndrome: A unifying hypothesis. J Nutr Biochem 2008; 19: 491-504.
[73]
V. Stratev, J. Petev, S. Galcheva, M. Peneva. The metabolic syndrome (MetS) in patients with chronic obstructive pulmonary disease (COPD) and its association with airway obstruction. Eur Respir J 2012; 40(Suppl. 56): 223.
[74]
Attvall S, Fowelin J, Lager I, et al. Smoking induces insulin resistance-a potential link with the insulin resistance syndrome. J Intern Med 1993; 233: 327-32.
[75]
Weitzman M, Cook S, Auinger P, et al. Tobacco smoke exposure is associated with the metabolic syndrome in adolescents. Circulation 2005; 112: 862-9.
[76]
Manson JE, Ajani UA, Liu S, et al. A prospective study of cigarette smoking and the incidence of diabetes mellitus among U.S. male physicians. Am J Med 2000; 109: 538-42.
[77]
Gamboa JL, Garcia-Cazarin ML, Andrade FH. Chronic hypoxia increases insulin-stimulated glucose uptake in mouse soleus muscle. Am J Physiol Regul Integr Comp Physiol 2011; 300: R85-91.
[78]
Jakobsson P, Jorfeldt L. Oxygen supplementation increases glucose tolerance during euglycaemic hyperinsulinaemic glucose clamp procedure in patients with severe COPD and chronic hypoxaemia. Clin Physiol Funct Imaging 2006; 26: 271-4.
[79]
Pour OR, Dagogo-Jack S. Prediabetes as a therapeutic target. Clin Chem 2011; 57: 215-20.
[80]
Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: Reconsideration of traditional contraindications. Eur J Intern Med 2002; 13(7): 428.
[81]
Hitchings AW, Archer JRH, Srivastava SA, Baker EH. Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. COPD 2015; 12(2): 126-31.
[82]
Sexton P, Metcalf P, Kolbe J. Respiratory effects of insulin sensitisation with metformin: A prospective observational study. COPD 2014; 11(2): 133-42.
[83]
WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and Management of Osteoporosis: Report of a WHO scientific group WHO technical report series; 920. Geneva: World Health Organization 2003.
[84]
Inoue D, Watanabe R. Ryo Okazaki. COPD and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis 2016; 11: 637-48.
[85]
Watanabe R, Tanaka T, Aita K, et al. Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab 2015; 33(4): 392-400.
[86]
Schnell KM, Weiss CO, Lee T, et al. The prevalence of clinically relevant comorbid conditions in patients with COPD: A cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012; 12(1): 26.
[87]
Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 10-4.
[88]
Graat-Verboom L, Wouters EF, Smeenk FW, et al. Current status of research on osteoporosis in COPD a systematic review. Eur Respir J 2009; 34: 209-18.
[89]
Bai P, Sun Y, Jin J, et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res 2011; 12: 157.
[90]
Lee J, Sandford A, Man P, et al. Is the aging process accelerated in chronic obstructive pulmonary disease? Curr Opin Pulm Med 2011; 17: 90-7.
[91]
Syed FA, Ng AC. The pathophysiology of the aging skeleton. Curr Osteoporos Rep 2010; 8: 235-40.
[92]
Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66(8): 699-708.
[93]
Persson LJ, Aanerud M, Hiemstra PS, et al. Chronic obstructive pulmonary disease is associated with low levels of vitamin d. PLoS One 2012; 7(6) e38934
[94]
Zhu B, Zhu B, Xiao C, Zheng Z. Vitamin D defciency is associated with the severity of COPD: A systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2015; 10: 1907-16.
[95]
Færk G, Çolak Y, Afzal S, Nordestgaard BG. Low concentrations of 25-hydroxyvitamin D and long-term prognosis of COPD: A prospective cohort study. Eur J Epidemiol 2018; 33(6): 567-77.
[96]
Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68: 259-70.
[97]
Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25(10): 2359-81.
[98]
Smith BJ, Laslett LL, Pile KD, et al. Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chron Respir Dis 2004; 1(3): 131-7.
[99]
Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev 2014; 23(133): 345-9.
[100]
Tselebis A, Pachi A, Ilias I, et al. Strategies to improve anxiety and depression in patients with COPD: A mental health perspective. Neuropsychiatr Dis Treat 2016; 12: 297-328.
[101]
Hynninen KM, Breitve MH, Wiborg AB, et al. Psychological characteristics of patients with chronic obstructive pulmonary disease: A review. J Psychosom Res 2005; 59: 429-43.
[102]
Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31: 58-69.
[103]
Cafarella A, Effing T, Barton C, et al. Management of depression and anxiety in COPD. In: Rabe K, Wedzicha J, Wouters E, Eds. COPD and comorbidity European Respiratory Monograph Number 59 March. 2013.
[104]
Schneider C, Jick SS, Bothner U, et al. COPD and the risk of depression. Chest 2010; 137: 341-7.
[105]
Ishii T, Wakabayashi R, Kurosaki H, et al. Association of serotonin transporter gene variation with smoking, chronic obstructive pulmonary disease, and its depressive symptoms. J Hum Genet 2011; 56: 41-6.
[106]
Norwood R. Prevalence and impact of depression in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2006; 12: 113-7.
[107]
Al-shair K, Kolsum U, Dockry R, et al. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res 2011; 12: 1.
[108]
Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J 2010; 35: 540-8.
[109]
Hanania N, Mullerova H, Locantore N, et al. Determinants of depression in the ECLIPSE COPD cohort. Am J Respir Crit Care Med 2011; 183: 604-11.
[110]
National Institute for Health and Clinical Excellence. CG91 Depression with a Chronic Physical Health Problem: NICE Guideline. London, UK: National Collaborating Centre for Mental Health; 2009. Available from: https: //www.nice.org.uk/ guidance/cg91 (Accessed 2018 July 20).
[111]
Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127: 1205-11.
[112]
Halvorsen T, Martinussen PE. Benzodiazepine use in COPD: Empirical evidence from Norway. Int J Chron Obstruct Pulmon Dis 2015; 10: 1695-702.
[113]
Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348: g445.
[114]
Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
[115]
Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122: 348-55.
[116]
El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK general practice research database. Aliment Pharmacol Ther 2009; 29: 470-80.
[117]
Sakae T, Pizzichini M, Teixeira P, de Silva R, Trevisol D, Pizzichini E. Exacerbations of COPD and symptoms of gastroesophageal reflux: A systematic review and meta-analysis. J Bras Pneumol 2013; 39(3): 259-71.
[118]
Lee AL, and Goldstein RS. Gastroesophageal reflux disease in COPD: Links and risks. Int J Chron Obstruct Pulmon Dis 2015; 10: 1935-49.
[119]
Terada K, Muro S, Ohara T, et al. Abnormal swallowing reflex and COPD exacerbations. Chest 2010; 137(2): 326-32.
[120]
Gross R, Atwood DJ, Ross S, Olszewski J, Eichhorn K. The coordination between breathing and swallowing in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179(7): 559-65.
[121]
Gadel AA, Mostafa M, Younis A, Haleem M. Esophageal motility pattern and gastroesophageal reflux in chronic obstructive pulmonary disease. Hepatogastroenterology 2012; 59(120): 2498-502.
[122]
Martinez CH, Okajima Y, Murray S, et al. COPDGene Investigators. Impact of self-reported gastroesophageal reflux disease in subjects from COPD Gene cohort. Respir Res 2014; 15: 62.
[123]
Liang B-M, Feng Y-L. Association of gastroesophageal reflux disease symptoms with stable chronic obstructive pulmonary disease. Lung 2012; 190: 277-82.
[124]
Katz PO, Gerson LB, Vela MF. Corrigendum: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108: 308-28.
[125]
Ingebrigtsen TS, Marott IL, Vestbo J, Nordestgaard BG, Hallas J, Lange P. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology 2015; 20(1): 101-7.
[126]
Baumeler L, Papakonstantinou E, Milenkovic B, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology 2016; 21(5): 883-90.
[127]
Ghebremariam YT, Cooke JP, Gerhart W, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med 2015a 13: 249.
[128]
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 501700629
[129]
Buscot M, Pottier H, Marquette CH, Leroy S. Phenotyping adults with non-cystic fibrosis bronchiectasis: A 10-Year cohort study in a French Regional University Hospital Center. Respiration 2016; 92(1): 1-8.
[130]
MartinezGarcia MA. Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis 2017; 12: 1401-11.
[131]
Stratev V, Petkova D, Dimitrova V, Petev J. Comorbidities of COPD in Bulgarian patients - prevalence and association with severity and inflammation. Folia Med (Plovdiv) 2018; 60(1): 102-9.
[132]
Gatheral T, Kumar N, Sansom B, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD 2014; 11(6): 605-14.
[133]
Singh R, Mackay A, Jadwiga A. Infection and comorbidity. In: Rabe K, Wedzicha J, Wouters E, Eds. COPD and comorbidity Wedzicha: European Respiratory Monograph Number 59 March. 2013.
[134]
Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: A systematic review and meta-analysis. PloS One 2016; 11(3) e0150532
[135]
Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbations indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170(4): 400-7.
[136]
Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-65.
[137]
Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67(12): 1075-80.
[138]
Santos S, Marin A, Serra-Batlles J, et al. Treatment of patients with COPD and recurrent exacerbations: The role of infection and inflammation. Int J Chron Obstruct Pulmon Dis 2016; 11: 515-25.
[139]
McNicholas W and Ruth Lee. In: Rabe K, Wedzicha J, Wouters E, Eds. Obstructive sleep apnoea and COPD. COPD and comorbidity. European respiratory monograph. Number 59, March 2013.
[140]
Kapur KV, Auckley HD, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American academy of sleep medicine clinical practice guideline. J Clin Sleep Med 2017; 13(3): 479-504.
[141]
Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013; 177(9): 1006-14.
[142]
Bednarek M, Plywaczewski R, Jonczak L, et al. There is no relationship between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome: A population study. Respiration 2005; 72(2): 142-9.
[143]
Soler X, Gaio E, Powell FL, et al. High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. Ann Am Thorac Soc 2015; 12: 1219-25.
[144]
Steveling EH, Clarenbach CF, Miedinger D, et al. Predictors of the overlap syndrome and its association with comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2014; 88: 451-7.
[145]
McNicholas WT. COPD-OSA Overlap syndrome: Evolving evidence regarding epidemiology, clinical consequences, and management. Chest 2017; 152(6): 1318-26.
[146]
Tuleta I, Stöckigt F, Juergens UR, et al. Intermittent hypoxia contributes to the lung damage by increased oxidative stress, inflammation, and disbalance in protease/antiprotease system. Lung 2016; 194: 1015-20.
[147]
Owens RL, Macrea M, and Teodorescu M. The overlaps of asthma or COPD with OSA: A focused review. Respirology 2017; 22: 1073-83.
[148]
Krachman SL, Tiwari R, Vega ME, et al. Effect of emphysema severity on the apnea-hypopnea index in smokers with obstructive sleep apnea. Ann Am Thorac Soc 2016; 13: 1129-35.
[149]
Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPD Gene Study. Chest 2011; 140: 626-33.
[150]
Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. Am J Respir Crit Care Med 2010; 182: 325-31.
[151]
Machado M-CL, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2010; 35: 132-7.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2019
Page: [90 - 101]
Pages: 12
DOI: 10.2174/1573398X14666181018101021

Article Metrics

PDF: 19
HTML: 2
EPUB: 1
PRC: 1